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INFUSIONS of the E-type prostaglandins are widely used to maintain patency of the ductus arteriosus in neonates with severely reduced pulmonary blood flow.1 7 Therapy usually continues for hours or days; the longest reported course of i.v. therapy has been 29 days in one infant. 7 We have briefly described the efficacy of long-term oral prostaglandin E2 (PGE2)8-10 and now report our experience of oral therapy in 12 patients. In particular, we tested (l) whether oral PGE2 consistently maintained ductus patency; (2) whether oral PGE2 could easily be substituted for i.v. therapy;
(3) the requirements of dosage and frequency of administration; and (4) whether the ductus remained PGE2-dependent after a period of months.
Patients and Methods
This study was approved by the Research Ethical Committees of both the Children's Hospital and the Central Birmingham Health District. Informed parental consent was obtained in each case.
Twelve infants with severely diminished pulmonary blood flow were treated with oral PGE2. Their mean weight was 2.90 kg. The clinical features are given in table 1. In patients 2, 3, 4, 6, 11 and 12, the surgeons considered the pulmonary arteries, as shown by angiography, to be too small to attempt a shunt operation. We hoped that prolonged treatment would encourage growth. In patients 1 and 7, PGE2 therapy was restarted after failure of a palliative operation.
The route and duration of PGE2 administration are shown in table 1. For oral therapy, tablets dissolved in water were first given through a nasogastric tube for 12-24 hours and were later given orally; in case 1, the i.v. preparation was given orally. Initially, oral PGE2 was given hourly, and each dose was 12-65 ,ug/kg. The dose and frequency of administration were adjusted depending on the clinical response. Cardiac catheterization was repeated in five infants at varying intervals after therapy had commenced.
In eight infants, the effects of PGE2 withdrawal and reintroduction were studied at various ages (table 2) . A radial arterial cannula (Abbocath 22G) was introduced for repeated blood oxygen analysis. Arterial oxygen tension (Pao2) was measured with an Instrumentation Laboratories pH/Blood Gas Analyzer (Model 413) and oxygen saturation (Sao2) with an American Optical Oximeter. For the purpose of analysis, Pao2 measurements were converted to Sao2 values using the appropriate oxygen dissociation curves." The significance of changes in Sao2 was obtained using the t test for paired data.'2 During the study, the skin temperature, radial arterial pressure and ECG were monitored continuously. Skin temperature was measured with a surface temperature probe (Yellow Springs Instruments, Series 409) taped just proximal to the great toe. Arterial pressure was measured with a Hewlett-Packard strain-gauge transducer (Model 1280) and pressure module (Model 78205).
At the time of study, seven of the eight patients had been stabilized on oral PGE2 therapy and one on an i.v. infusion. Repeat studies were performed in two infants. Most of the infants on oral therapy had been receiving hourly doses (table 2) up to the time of the withdrawal study. Normal feeding continued during the study. Sao2 was measured immediately before the last oral dose or before discontinuation of i.v. infusion, then at 15-minute intervals for the first hour and then every 30 minutes until the reintroduction of PGE2 therapy was clinically indicated. Additional blood samples were then taken to determine the rate of response to oral doses of PGE2.
In five patients, measurements of plasma PGE2 concentration were made to coincide with some of the arterial oxygen measurements. Plasma concentrations were measured by specific radioimmunoassay after extraction and chromatographic procedures described and validated previously.'3 Briefly, plasma was acidified to pH 3 with citric acid and extracted twice with a mixture of cyclohexane and ethyl acetate. Samples were then applied to microcolumns containing silicic acid, and, after a wash procedure, PGE2 was eluted with a methanolic mixture of cyclohexane and ethyl acetate. Recovery of PGE2 was monitored in each sample by the addition of 1200 cpm tritiated material before extraction began. The final radioimmunoassay has a sensitivity of 1 pg and 50% inhibition of initial binding at 5-6 pg. Buffer blanks run through the entire assay procedure were consistently undetectable. The intra-assay coefficient of variation was 8%. The significance of changes in plasma PGE2 concentration produced by PGE2 therapy was obtained using the t test for paired data. 12 At the initial and subsequent cardiac catheterization studies, the diameter of the main right pulmonary artery was measured on anteroposterior projections of the cineangiograms. The measurement was made just proximal to the division of the main right pulmonary artery, and correction was made for magnification.
Results
Dosage and Duration of PGE2 Therapy (table 1) The total course of treatment lasted 6-145 days and the oral course lasted 5-130 days. The oral dose ranged from 12-65 jig/kg, administered at intervals of 1-4 hours. The initial oral dose was 30-45 jig/ kg/hour, except in patient 1, who received 12 ,g/kg/ hour. After 1-3 weeks, the frequency was reduced in most cases to 2-hour intervals and in some, after 4 weeks, to 4-hour intervals. When PGE2 was infused i.v., the smallest effective dose was used. This was usually as low as 0.002-0.006 ug/kg/min.
Arterial Blood Oxygen Saturation
In each patient, oral PGE2 therapy produced an increase in oxygen saturation, usually within 15-20 minutes and invariably within 2 hours of commencing treatment. The mean Sao2 during oral therapy was not significantly different from the mean value during i.v. therapy ( fig. 1 ). In eight infants who had been stabilized on i.v. or oral therapy for periods of 1-10 weeks, Sao2 decreased during the period of 2-5 hours after the last dose of PGE2, from a mean of 75 + 7% to 57 ± 10% (+ SD) (table 2, figs. 2-5). Within 15 minutes of reintroduction of oral PGE2, Sao2 increased and by 30-45 minutes had almost reached prewithdrawal values (figs. [3] [4] [5] . However, in one patient (case 2) in whom Sao2 had been allowed to remain in the region of 40-50% for 2 hours, reintroduction of therapy was effective only after several hourly doses.
After the last dose of PGE2, Sao2 remained above 60% for at least 2 hours in seven studies and for at least 3 hours in four studies (table 2, figs. 2, 4, 5). The response of Sao2 to withdrawal and reintroduction of PGE2 therapy was not related to the age of infants at the time of the study. Plasma PGE2 Measurements (table 3) Plasma PGE2 concentrations were measured in patients 2, 3, 4, 6 and 7. After discontinuation of therapy, plasma PGE2 concentrations were 20-142 pg/ml in individual patients. A constant i.v. infusion of 0.002-0.006 ,ug/kg/min produced a mean plasma PGE2 concentration of 95 pg/ml. Within 15 minutes after an oral dose, the plasma concentration reached a mean of 77 pg/ml, and at 45-60 minutes reached a maximal mean value of 130 pg/ml. The change in plasma PGE2 concentration was accompanied in each case by the appropriate change in Sao2 or Pao2 (figs. 3 and 5). The dose response to oral PGE2 was tested *Duration of therapy is given in parentheses. Abbreviations: MPA = main pulmonary artery RPA = right pulmonarv artery; LPA = left pulmonary artery; IV venous; TGA = transposition of the great arteries; VSI) = ventricular septal defect; PA = pulmoniary atresia; IVS ventricular septum; TA = tricuspid atresia; V = ventricle: PDA = patent ductus arteriostus.
intrainteronly in one patient in whom the maximal plasma concentration almost doubled when the dose was doubled ( fig. 5 ).
Clinical Observations and Adverse Effects
The skin temperature followed the changes in Pao2 or Sao2 fairly closely. There were no significant changes in heart rate or blood pressure. Brief apneic spells occurred in three patients during i.v. therapy, but occurred in only one patient during oral therapy. Transient bradycardia accompanied the apnea. During i.v. therapy, two infants developed severe diarrhea that progressed to necrotizing enterocolitis in one. Both recovered after i.v. nutrition and continued i.v. Oxygen saturation values shown were those measured immediately before the last oral dose of PGE2 and at intervals after the dose or after discontinuation of i.v. infusion. *On i.v. infusion, 0.003 ,g/kg/min. . Arterial oxygen saturation (Sao2) and plasma PGE2 concentration in an infant given i. v. and oral PGE2. Three hours after discontinuation of i. v. infusion, oral PGE2 was given hourly (doses as shown). Both SacQ and plasma PGE, increased within 15 minutes of the first oral dose. in six of our 12 patients. All 12 patients gained weight during treatment with oral PGE2 for 1-5 months and those who were recatheterized had objective evidence of increased pulmonary arterial size.
The effectiveness of orally administered PGE2 in relaxing the ductus was demonstrated both by clinical improvement and by an increase in arterial oxygen content. The appreciable increase in plasma concentration of PGE2 within 15-30 minutes after an oral dose implies rapid absorption. An hourly oral dose of 30-45 ,g/kg resulted in a plasma PGE2 concentration comparable to that achieved by a continuous i.v. infusion. Although doses at 1-2-hour intervals may seem problematic, the ease of administration to the awake or sleeping baby surprised even the most skeptical.
Some of our planned studies were designed to determine the minimal requirements of PGE2 in terms of dosage frequency. Arterial oxygen tensions and saturations usually decreased to unacceptable levels if oral PGE2 was administered less frequently than every 2 hours during the first few weeks of therapy, but there were exceptions ( fig. 5 ). Perhaps this difficulty may be overcome by developing less rapidly metabolized derivatives of PGE15 or by a slow-release preparation.
None of our patients required an increased dose of PGE2 as time progressed. In fact, we could usually reduce the dose, but in no case could we stop the drug before surgery. Even after many months of responding to therapy, the ductus seemed to retain its preference to constrict when PGE2 was withdrawn for a matter of hours. In the one patient in whom the Sao2 had been allowed to remain at 40-50% for 2 hours, subsequent reintroduction of PGE2 resulted in slower improvement. This observation suggests that the degree of constriction of the ductus may determine its responsiveness to PGE2 therapy. Indeed TTIME (HOURS) suggested that when the ductus arteriosus is fully closed, it no longer responds to PGE. Complications of oral therapy were only seen early in the course of treatment. Four of 12 patients developed diarrhea during oral therapy, but it was usually transient and was simply and effectively managed by dose reduction in three patients, although one patient required prolonged i.v. infusion. When diarrhea occurred during i.v. therapy in two infants, it was more severe and progressed to necrotizing enterocolitis in one of them. Dose-related apnea occurred transiently in one infant during oral therapy but occurred in three patients during i. bradycardia, pyrexia or muscle twitching, which are commonly associated with i.v. therapy.3 7 14 Increase in skin temperature to normal values was probably a result of improved cardiac output'6 rather than of the systemic vasodilator effect of PGE217 because the increase in skin temperature was not associated with systemic hypotension. Thus, the incidence of adverse effects during i.v. and oral PGE2 therapy was similar, but the side effects associated with oral therapy were less problematic and could usually be managed by dose reduction. In the early part of our study we usually commenced treatment with an i.v. infusion of PGE2 and found that a dose as low as 0.002-0.006 ,g/kg/min was usually effective. This is less than 10% of the generally recommended dosage.9' 14 Because we showed that a similar clinical response was obtained by oral therapy, we now reserve i.v. therapy for infants who develop diarrhea that does not respond to a decreased oral dose.
We recommend an initial oral regimen of 30-45 ,ug/kg/hour. If there has been no significant response within 2 hours, the dose should be increased to a maximum of 65 1ig/kg/hour. After a few hours, it may again be possible to reduce the hourly dose. For the first 2 weeks of oral PGE2 therapy, hourly doses of 30-45 ,ug/kg are usually necessary. For practical reasons, we have tried to reduce the frequency rather than the size of the doses, but with little success in patients younger than age 3 weeks. It is always a matter of trial, preferably with the aid of repeated arterial oxygen measurements.
Oral administration of PGE2 proved effective for both short-and long-term therapy. The chief indication for long-term therapy is probably to ensure that the baby becomes a better surgical candidate, and this was indeed achieved. Our study has also provided new information concerning the response of the ductus to PGE over a period of many months. Our success in these cases has prompted us to extend the use of longterm oral PGE2 therapy to include infants with other complex congenital heart anomalies in which ductus patency is beneficial. 
